Jeffrey M. Goldberg
Equibles does not estimate personal net worth.
Get an email with a short summary when Spyre Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SYRE alertsAbout Jeffrey M. Goldberg
Jeffrey M. Goldberg is recorded as CEO at Spyre Therapeutics, Inc. (SYRE) since November 29, 2022. Spyre Therapeutics, Inc. reported in an 8-K filed May 19, 2023 that Jeffrey M. Goldberg was terminated as President and Chief Executive Officer, effective May 16, 2023. Spyre Therapeutics, Inc. reported in an 8-K filed November 30, 2022 that Jeffrey M. Goldberg was appointed Class III director, effective November 29, 2022. Spyre Therapeutics, Inc. reported in an 8-K filed November 30, 2022 that Jeffrey M. Goldberg was appointed President and Chief Executive Officer, effective November 29, 2022. The proxy statement of Spyre Therapeutics, Inc. reports total compensation of $830,207 for Jeffrey M. Goldberg in fiscal 2023, including a base salary of $248,471. Disclosed compensation is on record for 2 fiscal years. Spyre Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Spyre Therapeutics, Inc. includes Cameron Turtle (CEO, COO and Board Member), Cameron Turtle, DPhil (CEO and Board Member), James Kastenmayer (CEO) and 7 others.
“Effective May 16, 2023, the employment of each of Mr. Jeffrey Goldberg, the President and Chief Executive Officer of Aeglea BioTherapeutics, Inc. (the "Company"), and Mr. Jim Kastenmayer, the General Counsel of the Company, was terminated.”
“On November 28, 2022, the board of directors (the "Board") of Aeglea Biotherapeutics, Inc. (the "Company") appointed Jeffrey M. Goldberg, age 50, as President and Chief Executive Officer, and as a Class III director, effective November 29, 2022.”
Affiliation history
-
Current
2022-11-29–present
-
2022-01-01–2023-04-17
Last confirmed by a filing; no departure on record
-
Start not stated–2023-05-16
-
Start not stated–2023-05-16
Company network
Leadership on record at Spyre Therapeutics, Inc.
- Cameron Turtle CEO, COO, Board Member
- Cameron Turtle, DPhil CEO, Board Member
- James Kastenmayer CEO
- Scott Burrows CFO, Chief Accounting Officer
- Heidy Abreu King-Jones General Counsel
- Jonathan Alspaugh Chief Accounting Officer
- Steven Weber Chief Accounting Officer
- Jeffrey Albers Board Member
- Laurie Stelzer Board Member
- Mark McKenna Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Spyre Therapeutics, Inc. (SYRE) | Former President and Chief Executive Officer | $248,471 | $830,207 |
| 2022 | Spyre Therapeutics, Inc. (SYRE) | Former President and Chief Executive Officer | $54,616 | $1,832,485 |